Trevi Therapeutics (TRVI) Assets Average (2019 - 2026)

Trevi Therapeutics has reported Assets Average for 8 years, with the latest figure at $186.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 71.2% year-over-year to $186.5 million; the trailing twelve-month figure through Mar 2026 stood at $186.5 million (up 71.2% YoY), and the FY2025 full-year result was $152.2 million, up 51.94% from the prior year.
• Assets Average for Q1 2026 stood at $186.5 million, down from $196.4 million in the prior quarter.
• The five-year high for Assets Average was $203.8 million in Q3 2025, with the low at $34.4 million in Q1 2022.
• Average Assets Average over 5 years is $112.6 million, with a median of $104.9 million recorded in 2022.
• Year-over-year, Assets Average soared 258.74% in 2022 and fell 29.84% in 2024.
• Tracing TRVI's Assets Average over 5 years: stood at $125.7 million in 2022, then declined by 26.29% to $92.6 million in 2023, then slipped by 2.96% to $89.9 million in 2024, then surged by 118.45% to $196.4 million in 2025, then declined by 5.03% to $186.5 million in 2026.
• The last three Assets Average figures came in at $186.5 million (Q1 2026), $196.4 million (Q4 2025), and $203.8 million (Q3 2025), per Business Quant data.

Peer Comparison